Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM. A single-arm pilot phase II study of gefitnib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs 30:1660-1670, 2012. NIHMSID: NIHMS317711.
McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo MD, Speights R, Ivy P, Adamson PC, Blaney SM. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children’s oncology group study. Cancer 115(8):1765-75, 2009. NIHMSID: NIHMS314665.
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 50(8): 1237-43, 2009. PMID: 19617326.
Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27(27):4599-604, 2009. PMCID: PMC2754908.
Hinds PS, Oakes LL, Hicks J, Powell B, Srivastava DK, Spunt SL, Harper J, Baker JN, West NK, Furman WL. “Trying to be a good parent” as defined by interviews with parents who made phase I terminal care, and resuscitation decisions for their children. J Clin Oncol 27(35):5779-85, 2009. PMCID: PMC2793041.
McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo MD, Speights R, Ivy P, Adamson PC, Blaney SM. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Cancer 115(8):1765-1775, 2009. NIHMS134665.
Ross ME, Hicks J, Furman WL. Preschool as Palliative Care. J Clin Oncol 26(22): 3797-9, 2008.
Santana VM, Furman WL, McGregor L, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer 112(12): 2796-2801, 2008.
Hill DA, Furman WL, Billups CA, Riedley S, Cain AM, Rao BN, Pratt CB, Spunt SL. Colorectal carcinoma in childhood and adolescence: A clinicopathologic review of 77 cases. J Clin Oncol 25(36): 5808-14, 2007.
Wagner LM, Crews KR, Stewart DV, Rodriguez-Galindo C, McNall-Knapp RY, Albritton K, Pappo AS, Furman WL. Reducing Irinotecan-Associated Diarrhea in Children. Ped Blood CA 50(2):201-7, 2008.
Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt S, Stewart C, Houghton P, Gilbertson R, Furman WL. Phase I study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol 25:4806-4812, 2007.
Fouladi M, Furman WL, Chin T, Freeman BB, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group Report. J Clinic Oncol 24:3678-3685, 2006.
Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: Implications for diagnosis and screening. Pediatr Blood Cancer 47:851-854, 2006.
Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. CefiximeAllows Greater Dose-Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol 24(4):563-70, 2006.
Hinds PS, Drew D, Oakes LL, Fouladi M, Spunt S, Church C, Furman WL. End-of-Life Care Preferences of Pediatric Patients with Cancer. J Clin Oncol 23(36): 9146-54, 2005.
McGregor LM, Rao BN, Davidoff AM, Billups CA, Hongeng S, Santana VM, Hill DA, Fuller C, Furman WL. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. Cancer 104(12):2837-46, 2005.
Daw NC, Furman WL, Stewart CF, Iacona, LC, Drailo, M, Bernstein ML, Dancey, JE, Speights, RA, Blaney, SM, Croop, JM, Reaman, GH, Adamson, PC. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23:6172-6180, 2005.
Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, Stewart CF. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039-4047, 2005.
Navid F, Furman WL, Fleming M, Rao BN, Kovach S, Billups CA, Cain AM, Amonette R, Jenkins JJ, Pappo AS. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer 103:780-787, 2005.
Furman WL, Stewart CF, Kirstein M, Kepner JL, Berstein ML, Kung F, et al. A protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Onc 20(6):1617-1624, 2002.
Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ. Direct translation of a protracted irinotecan schedule from a xenograft Model to a Phase I trial in children. J Clin Oncol 17(6):1815-1824, 1999.
Furman WL, Luo X, Marina N, Garrison L, Pratt CB, Meyer WH. Comparison of cytokines in children with current solid tumors treated with intensive chemotherapy. J Pediatr Hematol Oncol 20(1):62-68, 1998.
Furman WL, Rodman JH, Tonda ME, Luo X, Arnold B, Marina N, Garrison L, Hanna R, Pratt CB, Meyer WH. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. Cancer Chemo Pharmacol 41:229-236, 1998.
Furman WL, Luo X, Fairclough D, Garrison L, Marina N, Pratt CB, Bleyer A, Meyer WH. A Phase I/II trial of subcutaneous Interlukin-1α in pediatric patients with malignant solid tumors. Med Pediatr Oncol 28:444-450, 1997.
Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14(5):1504-1509, 1996.
Furman WL. Cytokine support following cytotoxic chemotherapy in children. Int J Pediatr Hematol Oncol 2:163-171, 1995.
Furman WL, Strother D, McClain K, Bell B, Leventhal B, Pratt CB. A Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 11:2205-2210, 1993.
Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM, Meyer WH, Crist WM. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage-colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 9:1022-1028, 1991.
Furman WL, Pratt CB, Rivera GK, Krischer JP, Kamen BA, Vietti TJ. Mortality in pediatric phase I clinical trials. J Natl Cancer Inst 81:1193-1194, 1989
Furman WL, Rettenmier CW, Chen JH, Roussel MF, Quinn CO, Sherr CJ. Antibodies to distal carboxylterminal epitopes in the v‑fms‑coded glycoprotein do not cross‑react with the c‑fms gene product. Virology 152:432‑445, 1986.
Last update: February 2013